产品
编 号：F762932
分子式：C21H30Br3ClN6S
分子量：673.73
分子式：C21H30Br3ClN6S
分子量：673.73
产品类型
规格
价格
是否有货
结构图
CAS No: 3023471-40-8
产品详情
生物活性：
SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research.
体内研究：
SIRT6-IN-3 (HY-156027；20 mg/kg，腹腔注射；两天一次，连用四周) 在肿瘤小鼠模型中有抗肿瘤作用。SIRT6-IN-3 (HY-156027；20 mg/kg，腹腔注射；两天一次，连用四周) 在与吉西他滨 (比例 2 : 1 ) 联用时增强了吉西他滨的抗肿瘤作用。Animal Model:Tumor mouse model
Dosage:20 mg/kg (in combination with 10 mg/kg gemcitabine)
Administration:Intraperitoneal injection (i.p.); Once every 2 days for 4 weeks
Result:Inhibited the tumor mass 71.3% in mice with combinations of gemcitabine.Greatly increased the expression of apoptosis maker.
体外研究：
SIRT6-IN-3 (25 μM，48 小时) 诱导 PDAC 细胞周期阻滞和细胞凋亡。SIRT6-IN-3 (25 μM，72 小时) 通过抑制细胞信号通路来抑制胰腺癌细胞的增殖。
SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research.
体内研究：
SIRT6-IN-3 (HY-156027；20 mg/kg，腹腔注射；两天一次，连用四周) 在肿瘤小鼠模型中有抗肿瘤作用。SIRT6-IN-3 (HY-156027；20 mg/kg，腹腔注射；两天一次，连用四周) 在与吉西他滨 (比例 2 : 1 ) 联用时增强了吉西他滨的抗肿瘤作用。Animal Model:Tumor mouse model
Dosage:20 mg/kg (in combination with 10 mg/kg gemcitabine)
Administration:Intraperitoneal injection (i.p.); Once every 2 days for 4 weeks
Result:Inhibited the tumor mass 71.3% in mice with combinations of gemcitabine.Greatly increased the expression of apoptosis maker.
体外研究：
SIRT6-IN-3 (25 μM，48 小时) 诱导 PDAC 细胞周期阻滞和细胞凋亡。SIRT6-IN-3 (25 μM，72 小时) 通过抑制细胞信号通路来抑制胰腺癌细胞的增殖。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备